Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01646125
Title An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | POL | NOR | NLD | ITA | GBR | FRA | ESP

Facility Status City State Zip Country Details
Cedars Sinai Medical Center Dept.of Cedars-Sinai Med. Ctr. Los Angeles California 90048 United States Details
Maryland Oncology Hematology, P.A. SC Rockville Maryland 20850 United States Details
University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 5 Madison Wisconsin 53792-6164 United States Details
Novartis Investigative Site Marseille cedex 20 Bouches Du Rhone 13915 France Details
Novartis Investigative Site Creteil 94000 France Details
Novartis Investigative Site Villejuif Cedex 94805 France Details
Novartis Investigative Site Hong Kong Hong Kong Details
Novartis Investigative Site Monza MB 20900 Italy Details
Novartis Investigative Site Milano MI 20133 Italy Details
Novartis Investigative Site Parma PR 43100 Italy Details
Novartis Investigative Site Orbassano TO 10043 Italy Details
Novartis Investigative Site Koto ku Tokyo 135 8550 Japan Details
Novartis Investigative Site Seoul Korea 05505 Korea, Republic of Details
Novartis Investigative Site Seoul Korea 06351 Korea, Republic of Details
Novartis Investigative Site Seoul Seocho Gu 06591 Korea, Republic of Details
Novartis Investigative Site Seoul 03722 Korea, Republic of Details
Novartis Investigative Site Amsterdam 1081 HV Netherlands Details
Novartis Investigative Site Groningen 9713 GZ Netherlands Details
Novartis Investigative Site Bergen 5021 Norway Details
Novartis Investigative Site Oslo NO-0424 Norway Details
Novartis Investigative Site Gdansk 80 952 Poland Details
Novartis Investigative Site Barcelona Catalunya 08035 Spain Details
Novartis Investigative Site Madrid 28034 Spain Details
Novartis Investigative Site Kuei-Shan Chiang Taoyuan/ Taiwan ROC 33305 Taiwan Details
Novartis Investigative Site Taichung 407 Taiwan Details
Novartis Investigative Site Taipei 10048 Taiwan Details
Novartis Investigative Site Leicester LE1 5WW United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field